Objective: Smoking cessation treatment should be an important aspect of cancer care. In this study, we evaluated whether cancer-related disease factors adversely influence smoking cessation treatment.
| BACKGROUND
Tobacco use is known to cause cancer in at least 13 sites, and 30% of all cancer deaths are attributable to tobacco use. 1 Between 20% and 50% of adults diagnosed with cancer are smokers at the time of diagnosis, 2,3 and~15% of cancer survivors are smokers. 4, 5 A cancer diagnosis can be a teachable moment for smoking cessation, 6 as evidenced by higher quit rates among adults with a cancer diagnosis. 3, 7 Unfortunately, even if they initially quit smoking, smokers diagnosed with cancer have particularly high rates of relapse, and an estimated 50% of smokers continue to smoke after receiving a cancer diagnosis. 8 Cancer survivors who continue to smoke are less adherent to cancer treatment 9, 10 and have worse cancer outcomes. 11, 12 The National Comprehensive Cancer Network (NCCN) Clinical
Practice Guidelines for tobacco cessation, established in 2015, recommend that all patients with cancer who smoke are provided with evidence-based pharmacotherapy (especially combination nicotine replacement therapies or varenicline) and behavior therapy. 13 Unfortunately, despite the NCCN guidelines, most cancer patients do not receive treatment for nicotine dependence. In an international Internet survey, 90% of thoracic oncology providers reportedly asked their patients about tobacco use at their initial visit, but fewer than half engaged in further discussion of medication options or actively provided cessation assistance. 14 From the patient's perspective, thoracic and head and neck cancer survivors reported that 87% of their physicians asked about their tobacco use, but only 39% of their physicians suggested any sort of smoking cessation treatment. 15 Providers' perceptions of patients' inability to quit or resistance to treatment may be related to characteristics of the patient's cancer and treatment. For example, previous studies showed that smokers with cancer diagnoses that are perceived to be highly attributable to tobacco use are more likely to quit smoking than those with other cancer diagnoses 16 ; cancer patients who are currently or more recently undergoing treatment are less likely to be smoking than those who have completed treatment 17 ; and cancer patients have prolonged relapse rates. 8 However, few studies have examined the influence of these clinical factors on smoking cessation treatment adherence among smokers with cancer.
The purpose of the present exploratory analysis of an ongoing clinical trial was to determine whether cancer-related disease factors are associated with engagement or outcomes in a clinical trial of smoking cessation using varenicline, the most effective smoking cessation pharmacotherapy and first-line pharmacological treatment recommendation among smokers with cancer. 13 We hypothesized that cancer-related disease factors (smoking-related tumor site, current cancer treatment, shorter time since diagnosis, and higher health- 
| Participants
Adults who were at least 18 years of age were included in the trial if they reported smoking at least 5 cigarettes per week on average for the past 6 months and if they had been diagnosed with cancer or were actively in treatment for cancer within the past 5 years. Individuals were excluded or chose not to participate for: medical contraindications to using varenicline (n = 36), medication concerns (n = 10), practical barriers to participation (eg, time, distance; n = 31), daily use of other tobacco products (n = 5), already quit or current smoking cessation treatment (n = 64), DSM-IV diagnoses of psychotic disorder, bipolar disorder, or current suicidality (n = 74), not meeting study eligibility criteria (eg, no cancer diagnosis; n = 36), or were otherwise uninterested (n = 99). Cancer treatment included past-month surgery, chemotherapy, radiation treatment, hormone therapy, or any combination thereof, given previous findings that smokers in active cancer treatment were more likely to be abstinent than those who had completed treatment. 17 Time since diagnosis was calculated as the difference between the participant's self-reported date of diagnosis and his/her intake date in days, and divided by 30 for an approximate measure of months.
Health-related quality of life was assessed via the 12-item Short Form
Health Survey (SF-12), with questions such as, "During the past week, have you had any of the following problems with your work or other regular daily activities as a result of your physical health?" Total SF-12 scores were assessed continuously from 12 (poor health) to 47
(excellent health). 
| Smoking cessation treatment adherence

| Abstinence
Participants were classified as abstinent at Week 12 if they (1) did not report smoking any cigarettes in the past 7 days and (2) provided a CO breath sample < 10 ppm. Using an intent-to-treat model, participants were considered to be smoking if they (1) reported smoking any cigarettes in the past 7 days, (2) provided a CO breath sample ≥ 10 ppm, or (3) were unable to be reached or did not provide a breath sample.
| Covariates
Sociodemographic variables were self-reported at baseline, including sex, race/ethnicity (white vs racial/ethnic minority), age (years), education (≤high school degree or GED vs ≥some college), and employment status (employed vs unemployed/retired). Participants were queried as to their average number of cigarettes smoked per day and number of years smoking. Nicotine dependence was assessed on the Fagerström
Test of Nicotine Dependence, 23 which is scored from 0 (not dependent) to 10 (highly dependent).
| Data analysis
All data analyses were conducted using IBM SPSS Statistics Version 3 | RESULTS
| Sample characteristics
Characteristics of the sample (N = 144) are presented in Table 1 participants (56%) were classified as ≥80% adherent to varenicline. Four participants were excluded from analyses because they did not attend any sessions past the Pre-Quit session at which they received the medication and therefore did not report any medication timeline follow-back. Participants attended between 1 and 4 counseling sessions, with the majority of participants attending all 4 sessions (N = 108, 75%). There was a strong relationship between pill count and counseling attendance: participants who were adherent to medication were also likely to be adherent to counseling, r = 0.76, P < .001.
In Table 2 . The rate of medication adherence observed in this sample (56% were ≥80% adherent) was similar to the rates of adherence to varenicline among smokers in the general population, 22 patients in primary care 24 and a trial of varenicline among adults with thoracic cancer. 25 Counseling attendance rates were high, and 3 out of 4 participants attended all 4 counseling sessions. The importance of adherence is underscored by previous studies which have linked higher treatment adherence to a greater likelihood of smoking cessation, 22 including among the current sample of cancer survivors. 19 That HRQOL was associated with medication adherence is not surprising -HRQOL is often associated with smoking cessation treatment adherence, including among chronic disease populations. 26 In this sample in particular, those participants reporting lower HRQOL may have been experiencing more cancer-related side effects and therefore were less able to tolerate the side effects associated with varenicline, especially nausea. Bold indicates significance at P < .05. Abbreviations: CI, confidence interval; FTND, Fagerström Test of Nicotine Dependence; OR, odds ratio; SF-12, 12-item Short Form Health Survey.
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---indicates that this variable was not included in the models.
We did not find cancer site to be predictive of treatment adherence or abstinence, similar to observations of large prospective cohort studies 7, 27 and among participants in a tumor-site specific combined smoking, alcohol, and depression intervention. 28 
| Limitations
There are limitations to this study that warrant discussion. First, we were unable to examine subgroups (eg, exact tumor site) given the small numbers available for these groups. However, dividing the sample by tobacco-related site is of clinical relevance to oncology health care providers. Furthermore, we believe the diversity of our sample is a strength, as it represented diverse cancer-related characteristics and sociodemographic factors. Second, although we consider medication adherence and counseling adherence to be measuring two distinct constructs, there is inherent overlap in these measures, especially because the behavioral treatment included counseling regarding medication adherence. Third, our inclusion criteria allowed participants who reported smoking as few as 5 cigarettes per week to enroll, which may have limited our ability to reliably bioverify abstinence using exhaled carbon monoxide. However, participants reported smoking 14 cigarettes per day on average, with a minimum of 3 cigarettes per day, suggesting it is unlikely that participants were frequently misclassified by our bioverification. Fourth, all the cancer-related disease factors were self-reported because, although we collaborated with cancer centers, we recruited a community sample for this study; more accurate data may be obtained via chart review in future studies.
Finally, while the analysis was powered to detect small to medium effects, this was an exploratory analysis of an ongoing clinical trial, and therefore, it was not powered specifically to test the proposed hypothesis; however, these results represent good estimates of effect sizes that can be used to develop future proposals.
| Clinical implications
Our findings support the NCCN clinical practice guideline recommendations that first-line smoking cessation treatments should be offered to all cancer survivors, regardless of tumor site, current treatment, or time since diagnosis. 13 Unfortunately, most-targeted smoking cessation interventions among cancer survivors do not effectively increase abstinence rates among these high-risk patients. 8, 31 One-time behavioral counseling does not significantly increase abstinence rates, 32, 33 suggesting that more intensive interventions may be needed. The high level of adherence in the present study, especially to behavioral treatment, and previous findings that nearly 50% of smokers approached for cancer-related smoking cessation research studies agree to enroll 19, 25 suggest that many cancer survivors who smoke would be open to receiving more intensive smoking cessation assistance.
Regarding varenicline, few trials have been conducted in oncology populations, despite NCCN guidelines that recommend varenicline as a first-line treatment for smoking cessation. 13 Gosselin and colleagues evaluated a naturalistic smoking cessation program among 81 patients with head and neck cancer, and 14 of the 16 participants who reported abstinence at 1 month were prescribed varenicline. 34 In a 12-week feasibility trial, Park and colleagues observed higher quit rates among patients with thoracic tumors in a combined behavioral and varenicline intervention (34% abstinent) compared to usual care (14%). 25 In a large cohort of patients participating in a smoking cessation program in an oncology clinic,~50% of patients in the intervention group received varenicline with behavioral therapy, and those who took varenicline had greater odds of abstinence 6 months after the end of treatment compared with those who used nicotine replacement therapies. 35 The NCCN guidelines also recommend varenicline for patients who are not currently ready to quit smoking to facilitate reduction, with the ultimate goal of complete cessation. 13 Finally, lower doses of varenicline may reduce side effects, particularly among cancer patients undergoing treatment. 
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